ArticleCancer medicine2024

Real-world evidence of brigatinib as second-line treatment after crizotinib for ALK+ non-small cell lung cancer using South Korean claims data (K-AREAL).

Jeong Eun Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.